Nobuyuki Koga

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Association of Migraine Comorbidities with Quality of Life, Work Productivity and Daily Activities: Survey and Medical Claims Data in Japan.

Association of Migraine Comorbidities with Quality of Life, Work Productivity and Daily Activities: Survey and Medical Claims Data in Japan.

Journal: Advances in therapy

Published: March 04, 2025

Concentrations and dietary exposure to persistent organic pollutants and naturally occurring halogenated contaminants in edible shrimp from Japanese coastal waters and the South China Sea.

Concentrations and dietary exposure to persistent organic pollutants and naturally occurring halogenated contaminants in edible shrimp from Japanese coastal waters and the South China Sea.

Journal: Chemosphere

Published: December 15, 2024

Quality of life and work productivity and activity impairment among online survey respondents with migraine across a range of headache frequency.

Quality of life and work productivity and activity impairment among online survey respondents with migraine across a range of headache frequency.

Journal: Frontiers in neurology

Published: May 30, 2024

Characteristics of patients who seek medical attention for headache and those who do not: cross-sectional survey and linked medical claims data analysis in Japan.

Characteristics of patients who seek medical attention for headache and those who do not: cross-sectional survey and linked medical claims data analysis in Japan.

Journal: BMJ open

Published: April 29, 2024

Levels and spatial profile of per- and polyfluoroalkyl substances in edible shrimp products from Japan and neighboring countries; a potential source of dietary exposure to humans.

Levels and spatial profile of per- and polyfluoroalkyl substances in edible shrimp products from Japan and neighboring countries; a potential source of dietary exposure to humans.

Journal: Environment international

Published: November 17, 2023

A study to investigate the prevalence of headache disorders and migraine conducted using medical claims data and linked results from online surveys: post-hoc analysis of other headache disorders.

A study to investigate the prevalence of headache disorders and migraine conducted using medical claims data and linked results from online surveys: post-hoc analysis of other headache disorders.

Journal: BMC neurology

Published: September 27, 2023

Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.

Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.

Journal: Psychiatry and clinical neurosciences

Published: September 07, 2023

Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials.

Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials.

Journal: Headache

Published: April 25, 2023

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Journal: Neurology and therapy

Published: April 11, 2023

A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.

A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.

Journal: Expert opinion on drug safety

Published: December 29, 2022

Correction: A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan.

Correction: A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan.

Journal: The journal of headache and pain

Published: December 28, 2022

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.

Journal: Journal of pain research

Published: October 26, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026